# Pizarra — PT-pseudo_d3d6b421d0aa (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d3d6b421d0aa
Task: 1

Encounter: Urology - outpatient on 09 Feb 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 8.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.202 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 7.4 ng/mL
  - Prostate volume: 42.65 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8539465 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 8.6 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 43 mL. DRE nodus. csPCa 0.85.

Vitals: weight 74 kg, height 170 cm, BMI 25.6, BP 164/61 mmHg, HR 77 bpm. Smoking: Non-smoker.

Chief complaint: Ongoing assessment of established prostate malignancy alongside a persistent upward PSA trend.

History: At 68 years of age, this self-employed carpentry contractor entered clinical review in early 2023 after an unexpected PSA spike, building upon a prior biopsy bucket marked Positive. He endures marked lower urinary tract obstruction, scoring 30 out of 35 on the IPSS, driven mainly by frequent nighttime urination and a diminished urinary stream that heavily disrupts his everyday activities. Though married, he maintains a solo household; his grown daughter acts as his main point of contact and handles all medical paperwork with his permission. He refrains from tobacco use entirely, leads a largely sedentary routine punctuated by brief walks, and limits alcohol intake to roughly nine units weekly. Unexplained weight loss and skeletal pain are firmly denied. Recent sleep disturbances stem chiefly from nocturia and occupational pressures.

Physical examination: DRE: The prostate presents as asymmetrically enlarged, harboring a distinct firm nodule within the right posterior peripheral zone. Vital signs record a blood pressure of 164/61 mmHg and a steady heart rate of 77 beats per minute. Body mass index registers at 25.6 kg/m². Systemic screening shows no peripheral lymphadenopathy or hepatosplenomegaly.

Patient info: self-employed contractor (carpentry); Married; Lives alone; adult daughter is primary contact.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 9 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 30/35 (severe LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.32 +/- 0.19   (95% CI 0.03-0.73)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.8 effective neighbours out of 10; 0 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=8.6, age=68.0, psad=0.202, dre_ord=1.0, vol=42.65, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5, PSA=8.6, prior biopsy Positive, csPCa probability=0.8539465) and failed to incorporate the crucial context of the retrieved documents, such as the specific MRI findings, PSA trajectory, or laboratory panel results. Specifically, it did not weigh the patient's severe LUTS (IPSS 30/35) or the DRE finding of a nodule, which are clinical factors that might modify the risk assessment.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a wide uncertainty interval (0.32 +/- 0.19), indicating the classifier is genuinely unable to distinguish between the two outcomes. This wide interval suggests the panel is highly ambiguous. Furthermore, the prior ignores the guideline context that a PI-RADS 5 lesion places the patient in a high-risk category, which contradicts the statistical suggestion to defer.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes
laboratory panel
The retrieval of the radiology report is critical because the guideline suggests that the MRI findings determine if a repeat biopsy is warranted, as a stable MRI might exclude it in low-risk scenarios.
<|channel>thought
Thinking Process:

1.  **Analyze the Request:** The user wants me to act as LLM-1-GAP-ANALYST, focusing solely on doubt. I must follow the four mandated headings: WHAT THE PRIOR CANNOT SEE, WHY THE SUGGESTION COULD BE WRONG, WHAT TO RETRIEVE, and GUIDELINE ANCHOR. I must use the search results and the blackboard data.

2.  **Review Blackboard Data:**
    *   **Patient Data:** 68M, PSA 8.6, PI-RADS 5, PSAD 0.202, PSA velocity 0.77 ng/mL/yr, Prior PSA 7.4, Volume 42.65 mL, Prior biopsy Positive, csPCa predicted probability 0.8539465. DRE: Nodus. Severe LUTS (IPSS 30/35).
    *   **Expert-Prior:** Suggests NO BIOPSY (0.32 +/- 0.19). Notes it only read visible panel data.
    *   **Expert-Protocol:** States the decision is undetermined by the panel; requires retrieved documents (MRI prose, trajectory, etc.).
    *   **Search Results:** Provided context on PI-RADS, PSA-D, and biopsy risk (e.g., PI-RADS 5 has an 83% detection rate for csPCa).

3.  **Draft Content based on Mandate (LLM-1-GAP-ANALYST):**

    *   **WHAT THE PRIOR CANNOT SEE:** Focus on the missing clinical context that influences risk beyond the raw numbers.
    *   **WHY THE SUGGESTION COULD BE WRONG:** Focus on the ambiguity of the prior and the conflict between high-risk imaging (PI-RADS 5) and the statistical deferral.
    *   **WHAT TO RETRIEVE:** List the documents explicitly mentioned as necessary by the protocol expert and relevant to the guideline search.
    *   **GUIDELINE ANCHOR:** Quote or paraphrase the relevant guideline finding that constrains the decision.

4.  **Refine and Check Constraints:**
    *   Max 220 words. (Check length during drafting).
    *   No recommendation (yes/no).
    *   Only doubt/analysis.
    *   Strictly adhere to the four headings.
    *   Only use information from the blackboard or retrieved search results.

5.  **Final Review against Rules:** The output must be analytical doubt, not a summary or decision. (Self-Correction: Ensure the retrieval requests are specific and actionable.) (The drafted plan looks compliant.)<channel|>WHAT THE PRIOR CANNOT SEE
The statistical prior failed to incorporate the clinical severity indicators present in the record, such as the patient's severe LUTS (IPSS 30/35) and the physical finding of a distinct firm nodule on DRE. It also did not weigh the high-risk nature of a PI-RADS 5 score against the prior positive biopsy status.

WHY THE SUGGESTION COULD BE WRONG
The prior's wide uncertainty interval (0.32 +/- 0.19) indicates the panel is highly ambiguous, suggesting the classifier cannot resolve the conflict between the high PI-RADS score and the statistical tendency to defer. This ambiguity is compounded by the guideline criterion stating the decision is undetermined without retrieved documents.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes
laboratory panel

GUIDELINE ANCHOR
The guideline search indicates that the PI-RADS 5 score is associated with an 83% detection rate for clinically significant prostate cancer, which constrains the decision by establishing a high inherent risk profile for the patient.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
RAD-2025-0205: PI-RADS 5 lesion in the right posterior peripheral zone, measuring 18 x 15 x 12 mm. No extraprostatic extension or suspicious pelvic lymphadenopathy detected.
get_psa_trend
The PSA trend shows fluctuation: 8.6 ng/mL (Apr 2023), 4.4 ng/mL (Oct 2023), 8.4 ng/mL (Mar 2024), 4.1 ng/mL (Aug 2024), and 8.6 ng/mL (Feb 2025).
get_previous_notes
20 Feb 2023: Initial workup triggered by an incidental PSA reading of 5.5 ng/mL back in April 2023. Follow-up surveillance showed a steady upward trend, leading to a transrectal ultrasound-guided needle sampling that confirmed adenocarcinoma.
get_lab_results
PSA: 8.6 ng/mL (20 Jan 2025). %Free PSA: 28% (20 Jan 2025). eGFR: >60 mL/min/1.73m2 (20 Jan 2025).

NOT RETRIEVED
The pathology report was not retrieved because the task specified that only the four documents (MRI, PSA history, previous notes, lab results) were available for this decision.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling Now:
- MRI report: PI-RADS 5 lesion (18 x 15 x 12 mm) in the right posterior peripheral zone.
- PSA trend: Fluctuating trend with recent high values (8.6 ng/mL in Feb 2025).
- Previous notes: Prior biopsy confirmed adenocarcinoma, and the patient is under specialist review.

AGAINST Sampling Now:
- Previous notes: Prior biopsy confirmed adenocarcinoma, suggesting the need for surveillance rather than immediate re-biopsy unless criteria are met.

WHERE THIS LEANS
The evidence strongly points toward further investigation due to the high-risk PI-RADS 5 finding and the persistent, high PSA level, which contradicts the statistical prior's suggestion to defer.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Biopsy is recommended because the retrieved evidence shows a high-risk PI-RADS 5 lesion and a persistent, high PSA level of 8.6 ng/mL, which contradicts the guideline criterion that requires retrieved documents to settle the case. The prior positive biopsy status is noted, but the absence of a documented ISUP grade or comparison against a previous MRI means the decision is not clear. The evidence converges on proceeding with sampling to determine the characteristics of the lesion.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
